eCTD as your strategic asset: Rethinking eCTD in Modern Regulatory Affairs

In today’s pharmaceutical landscape, regulatory submissions are a decisive factor in speed to market, compliance, and overall business performance. At the center of this transformation lies the electronic Common Technical Document (eCTD), which has become the global standard for submissions across major health authorities.

For companies operating in Europe, the United States, Canada, and other regulated markets, eCTD is not optional. Agencies such as the EMA, FDA, MHRA, and Health Canada require most submissions to follow this structured electronic format, in line with strict and evolving technical specifications.

Yet, while the requirement itself is clear, the way organizations approach eCTD varies widely — and this is where the real difference is made.

The complexity of eCTD: Explained   

At first glance, eCTD is designed to simplify regulatory submissions — and it does. However, it also introduces a level of technical and operational complexity that is often underestimated.

A key challenge is the need for specialized expertise. Managing eCTD submissions, especially with the transition to eCTD 4.0, requires a combination of regulatory knowledge and technical skills that can be difficult to build and maintain internally. This often leads to reliance on a limited number of experts and increases operational risk.

This complexity is further amplified by the systems supporting submissions. Regulatory Information Management Systems (RIMS) must be continuously maintained updated, and carefully managed. Even small operational errors can affect dossier integrity and trigger validation issues. As regulatory timelines remain strict, any issue can jeopardize submissions and quickly impact approvals and market access.

The transition to eCTD 4.0 adds another layer of complexity, with a new approach for sequence preparation and electronic dossier management, evolving specifications and varying levels of adoption across regions, making global submission management more challenging.

In many organizations, eCTD activities are still seen as purely operational. As a result, their importance is often underestimated until issues arise. When this happens, teams must become focus and reactive, spending valuable time resolving technical issues, affecting day-to-day activities.

 

eCTD as a strategic asset

Forward-looking organizations are shifting their perspective, integrating eCTD into a broader digital regulatory strategy.

This approach focuses on building structured, end-to-end processes that ensure submission readiness at every stage. It includes proactive validation activities to prevent potential issues, strong governance of RIMS platforms to maintain stability and compliance, and continuous attention to data quality.

Lifecycle management also becomes a key priority. Maintaining consistent, accurate dossiers throughout the product lifecycle — across all kind of regulatory procedures as variations, renewals, and updates — requires a controlled and well-managed environment, always compliant with the latest eCTD guidelines.

When these elements are aligned, eCTD becomes a driver of efficiency, enabling organizations to reduce rework, improve submission timelines, and scale their operations across multiple markets.

 

In-House Vs. Outsourcing

Managing everything in-house requires continuous investment and increases reliance on limited internal resources, which can become a constraint as workload grows.

Outsourcing, on the other hand, offers access to experienced professionals who bring both technical and regulatory expertise. When structured effectively, it simplifies operations — particularly when a single point of contact ensures coordination between internal teams and system providers and support in case of technical issues raised by the Health Authorities.

While cost is often perceived as a barrier, in practice, external support frequently reduces inefficiencies, prevents costly delays, and improves overall productivity. Most importantly, it allows internal teams to focus on strategic activities rather than technical execution.

 

Frequently Asked Questions About eCTD  

To address the most common concerns from Regulatory Affairs leaders, here are some key questions and answers:

 

  • Is eCTD mandatory for regulatory submissions? 

Yes. For most procedures, eCTD is mandatory across major health authorities, including EMA, FDA, Health Canada, MHRA, and Swissmedic. Submissions must comply with mandatory and evolving specifications and validation criteria, making both compliance and execution critical. 

 

  • Which countries accept eCTD submissions? 

eCTD format is mandatory for most of the procedures in Europe in the different registration type (Centralised, Decentralised, Mutual Recognition and National Procedures) in the US, Canada, Switzerland, and Australia. MAAs are also mandatory in South Africa, Thailand, China (for some kind of registration type) and some GCC countries and accepted in and other regions. 

 

  • What is the latest eCTD version? 

The current ICH version in use is eCTD v3.2.2, adopted across major regions such as the EU, US, Canada, Switzerland, and GCC. Each region also defines its own Module 1 specifications with specific validation criteria (e.g., EU Specification 3.1.1 with Validation Criteria v8.2).

 However, the ICH eCTD version v4.0 is already in use in Japan and several regions as Europe, Canada and US are performing pilot phases in order to implement this update version in the upcoming years.  

 

  • Is an eCTD application the same as a dossier? 

 Not exactly. The dossier represents the regulatory content of a submission, while eCTD is the electronic format used to structure and submit that content to competent authorities. 

 

  • What is the process for electronic submission via eCTD? 

The eCTD submission process includes document preparation and optimization (ensuring PDF compliance), creation of the sequence structure, and document integration (including metadata and envelope information). This is followed by hyperlinking (if required), publishing, validation, and submission to competent authorities via national portals. 

 

Why choose PQE Group for eCTD publishing services?

While eCTD is mandatory, struggling with it isn’t.

Managing eCTD effectively requires specialized expertise, structured processes, and continuous regulatory monitoring and alignment. PQE supports organizations by combining all these elements into a fully integrated service model.

From end-to-end eCTD publishing to lifecycle management, ensuring that every submission is accurate, compliant, and ready for approval. Beyond execution, PQE acts as a true partner in digital Regulatory Affairs, helping organizations navigate complexity while improving efficiency.

What makes PQE different is its ability to combine hands-on operational support with strategic oversight:

  • A dedicated single point of contact
  • Expert technical validation and issue resolution
  • Direct coordination with system providers
  • Support in publishing planning
  • Lifecycle management and metadata quality control
  • Proactive monitoring of eCTD 4.0 evolution

By reducing operational complexity and strengthening control over regulatory processes, PQE enables your teams to focus on high-value activities while ensuring submission excellence.

eCTD Regulatory Affairs_Blog

Want to know more?

 Visit our Regulatory Affairs dedicated page 

Bring your product into the next generation.

Risking inspection failures is a cost no company can afford: get in touch with us and learn more together with our experts. 

Contact us